<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03221088</url>
  </required_header>
  <id_info>
    <org_study_id>GenSci 033 CT-one year</org_study_id>
    <nct_id>NCT03221088</nct_id>
  </id_info>
  <brief_title>A Study of PEG-somatropin in the Treatment of Children With Idiopathic Short Stature</brief_title>
  <official_title>Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Idiopathic Short Stature: A Controlled, Prospective, Randomized, Multicenter Phase-II Study With An Untreated Control Group.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GeneScience Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tongji Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Hospital of Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Affiliated Hospital of Jiangnan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital with Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Children's Hospital of Zhejiang University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Children's Hospital of Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>GeneScience Pharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to explore the optimal dose of pegylated recombinant human growth hormone&#xD;
      (PEG-rhGH) injection to treat children with idiopathic short stature (ISS), evaluate its&#xD;
      safety and efficacy, and provide scientific and reliable evidence for the medication dosage&#xD;
      in Phase III clinical study.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">June 2015</start_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Height Standard Deviation Score for Chronological Age (ΔHtSDSCA)</measure>
    <time_frame>Baseline，52 weeks</time_frame>
    <description>Change in Height Standard Deviation Score for Chronological Age (ΔHtSDSCA) from Baseline to 52 weeks；ΔHtSDSCA=(height Yx - reference mean for CA Yx) / reference SD for CA Yx (Yx refers to the height value at particular timepoint x)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Annualized Height Velocity</measure>
    <time_frame>Baseline，52 weeks</time_frame>
    <description>Annualized Height Velocity=12×(Height Yx - Height at Baseline)/(Date of Yx - Date of Baseline) (Yx refers to the height value at particular timepoint x)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Bone Maturation</measure>
    <time_frame>Baseline，52 weeks</time_frame>
    <description>Bone Maturation=(BA Yx-BA at Baseline)/(Date of Yx - Date of Baseline) (Yx refers to the BA value at particular timepoint x)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in IGF-1 Standard Deviation Score (IGF-1 SDS)</measure>
    <time_frame>Baseline，52 weeks</time_frame>
    <description>GF-1 SDS=(IGF-1 Yx - reference mean for CA Yx) / reference SD for CA Yx (Yx refers to the IGF-1 value at particular timepoint x)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IGF-1/IGFBP-3 molar ratio at 52 weeks</measure>
    <time_frame>Baseline，52 weeks</time_frame>
    <description>IGF-1/IGFBP-3 molar ration=[IGF-1(ng/ml)/7.6]/[IGFBP-3 (ng/ml)/25.75]</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Dwarfism</condition>
  <arm_group>
    <arm_group_label>Jintrolong® low dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PEG-rhGH Injection (27IU/4.5mg/0.5ml/bottle) 0.1 mg/kg/w by subcutaneous injection for 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Jintrolong® high dose group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PEG-rhGH Injection (27IU/4.5mg/0.5ml/bottle) 0.2 mg/kg/w by subcutaneous injection for 52 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Negative control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Untreated Control Group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Jintrolong® low dose group</intervention_name>
    <description>PEG-somatropin 0.1mg/kg/wk by weekly subcutaneous injection for 52 weeks.</description>
    <arm_group_label>Jintrolong® high dose group</arm_group_label>
    <arm_group_label>Jintrolong® low dose group</arm_group_label>
    <other_name>PEG-somatropin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Jintrolong® high dose group</intervention_name>
    <description>PEG-somatropin 0.2 mg/kg/wk by weekly subcutaneous injection for 52 weeks.</description>
    <arm_group_label>Jintrolong® high dose group</arm_group_label>
    <arm_group_label>Jintrolong® low dose group</arm_group_label>
    <other_name>PEG-somatropin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Boys are between 4 and 9 years of age and girls are between 4 and 8 years of age.&#xD;
&#xD;
          -  Height &lt;-2 SD for chronological age.&#xD;
&#xD;
          -  Growth velocity&lt;5.0 cm/yr.&#xD;
&#xD;
          -  GH peak concentration ≥10.0 ng/mL in two different stimulation tests.&#xD;
&#xD;
          -  The difference of bone age (BA) and chronological age (CA) is within -2 to +2.&#xD;
&#xD;
          -  IGF-1 concentration is between -2 SDS to +2 SDS.&#xD;
&#xD;
          -  Prepubertal Status(Tanner Stage I).&#xD;
&#xD;
          -  Birth weight within the normal range.&#xD;
&#xD;
          -  Growth hormone treatment-naive.&#xD;
&#xD;
          -  Subjects are willing and able to cooperate to complete scheduled visits, treatment&#xD;
             plans and laboratory tests and other procedures, to sign informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with abnormal liver and kidney functions (ALT &gt; upper limit of normal value;&#xD;
             Cr &gt; upper limit of normal value).&#xD;
&#xD;
          -  Subjects are positive for anti-HBc, HbsAg or HbeAg in Hepatitis B virus tests.&#xD;
&#xD;
          -  Subjects with known highly allergic constitution or allergy to investigational product&#xD;
             or its excipient.&#xD;
&#xD;
          -  Subjects with systemic chronic disease and immune deficiency.&#xD;
&#xD;
          -  Patients diagnosed with tumor.&#xD;
&#xD;
          -  Patients with mental disease.&#xD;
&#xD;
          -  Patients with other types of abnormal growth and development.&#xD;
&#xD;
               1. Growth hormone deficiency (GHD) (confirmed by GH stimulation test);&#xD;
&#xD;
               2. Turner syndrome (confirmed by karyotype test of girls);&#xD;
&#xD;
               3. Noonan syndrome (hypertelorism, pectus carinatum, hypophrenia, frequently with&#xD;
                  skin disease and congenital heart disease, missense mutation of the protein&#xD;
                  tyrosine phosphatase, non-receptor type 11 (PTPN11) gene on chromosome 12 for&#xD;
                  half of the patients, for both male and female patients);&#xD;
&#xD;
               4. Laron sydrome (confirmed by IGF-1 generation test);&#xD;
&#xD;
               5. Small for gestational age ( the birth height or weight is below the tenth&#xD;
                  percentile or 2 SD, with catch-up growth uncompleted at 2 years old).&#xD;
&#xD;
          -  Growth disorders caused by malnutrition or hypothyroidism (thyroid function test).&#xD;
&#xD;
          -  Congenital skeletal abnormalities or scoliosis, claudication.&#xD;
&#xD;
          -  Subjects with impaired glucose regulation (IGR) (including impaired fasting glucose&#xD;
             (IFG) and/or impaired glucose tolerance (IGT) ) or diabetes).&#xD;
&#xD;
          -  Subjects with abnormal electrolyte, blood gas analysis (vein), creatine kinase.&#xD;
&#xD;
          -  Subjects who took part in other clinical trials within 3 months.&#xD;
&#xD;
          -  Subjects who received medications which may interfere GH secretion or GH function, or&#xD;
             other hormones within 3 months (such as sex steroids, glucocorticoids, etc.).&#xD;
&#xD;
          -  For patients with potential high tumor risks such as tumor markers exceed normal range&#xD;
             and some other relative information, they may be excluded from the treatment.&#xD;
&#xD;
          -  Other conditions which is inappropriate for this study in the opinion of the&#xD;
             investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>9 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaoping Luo</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Pediatrics of Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yanlin Chen</last_name>
    <phone>+86-60871786-8197</phone>
    <email>chenyanlin@gensci-china.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaoping Luo, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiated Hospital of Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuhua Hu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Jiangnan University</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhuangjian Xu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongwei Du, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junfen Fu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Children's Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Feihong Luo, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Children's Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pin Li, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>July 14, 2017</study_first_submitted>
  <study_first_submitted_qc>July 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 18, 2017</study_first_posted>
  <last_update_submitted>July 17, 2017</last_update_submitted>
  <last_update_submitted_qc>July 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dwarfism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

